Amgen disclosed detailed VESALIUS-CV trial data showing its PCSK9 monoclonal antibody Repatha reduced major cardiovascular events by 25% and prevented first heart attacks by 36% in high-risk patients without prior heart attack or stroke. Results, published in the New England Journal of Medicine and presented at the AHA meeting, also showed reductions in coronary death and fewer revascularization procedures. The findings expand Repatha’s clinical profile into primary prevention for selected high-risk populations.